Emicizumab-kxwh
Class: Hemostatics
Chemical Name: Immunoglobulin G4, anti-(human blood-coagulation factor IXa/blood-coagulation factor IX) (human-Rattus norvegicus monoclonal Q499-z121/J327-z119/L404-κ heavy chain), disulfide with human-Mus musculus-Rattus norvegicus monoclonal Q499-z121/J327-z119/L404-κ light chain, dimer with immunoglobulin G4, anti-(human blood-coagulation factor Xa/blood-coagulation factor X) (human-Mus musculus monoclonal Q499-z121/J327-z119/L404-κ heavy chain), disulfide with human-Mus musculus-Rattus norvegicus monoclonal Q499-z121/J327-z119/L404-κ light chain
Molecular Formula: C6434H9940N1724O2047S45
CAS Number: 1610943-06-0
Brands: Hemlibra
Warning
Warning: Thrombotic Microangiopathy and Thromboembolism
See full prescribing information for complete boxed warning.
Cases of thrombotic microangiopathy and thrombotic events were reported when on average a cumulative amount of >100 U/kg/24 hours of activated prothrombin complex concentrate (aPCC) was administered for 24 hours or more to patients receiving emicizumab-kxwh prophylaxis. Monitor for the development of thrombotic microangiopathy and thrombotic events if aPCC is administered. Discontinue aPCC and suspend dosing of emicizumab-kxwh if symptoms occur.
Introduction
Emicizumab-kxwh is a hemostatic.
Uses for Emicizumab-kxwh
Emicizumab-kxwh has the following uses:
Emicizumab-kxwh is a bispecific factor IXa- and factor X-directed antibody indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients with hemophilia A (congenital factor VIII deficiency) with factor VIII inhibitors.
Emicizumab-kxwh Dosage and Administration
General
Emicizumab-kxwh is available in the following dosage form(s) and strength(s):
Injection: 30 mg/mL in a single-dose vial.
Injection: 60 mg/0.4 mL in a single-dose vial.
Injection: 105 mg/0.7 mL in a single-dose vial.
Injection: 150 mg/mL in a single-dose vial.
Dosage
It isessentialthat the manufacturer's labeling be consulted for more detailed information on dosage and administration of this drug. Dosage summary:
Adults
Recommended dose is 3 mg/kg by subcutaneous injection once weekly for the first 4 weeks, followed by 1.5 mg/kg once weekly.
See Full Prescribing Information for important preparation and administration instructions.
